Moreover, numerous preclinical studies have demonstrated the role of STING signaling, particularly in APCs, on tumor antigen cross-presentation and antitumor T cell immunity after various treatments, e.g., chemo/radiation (9), CD47 blockade (10), telomerase-targeting agents (11), and DNA damage (12). This evidence concerns the gene CD47 and neoplasm.